[
  {
    "ts": null,
    "headline": "Former Top FDA Official, Forced Out by Kennedy, Lands at Eli Lilly",
    "summary": "Dr. Peter Marks, the top Food and Drug Administration official whose forced resignation earlier this year set off a panic among biotech investors, is now an executive at  Eli Lilly  the company said on Tuesday.  Marks stepped down as the chief of the FDA’s Center for Biologics Evaluation and Research in March.  Lilly says he started work this month.",
    "url": "https://finnhub.io/api/news?id=3890c98a897fdd4de3d071058b5b8af7e181b9ef403719bfec098df3d4b0e8a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759871040,
      "headline": "Former Top FDA Official, Forced Out by Kennedy, Lands at Eli Lilly",
      "id": 137007950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Dr. Peter Marks, the top Food and Drug Administration official whose forced resignation earlier this year set off a panic among biotech investors, is now an executive at  Eli Lilly  the company said on Tuesday.  Marks stepped down as the chief of the FDA’s Center for Biologics Evaluation and Research in March.  Lilly says he started work this month.",
      "url": "https://finnhub.io/api/news?id=3890c98a897fdd4de3d071058b5b8af7e181b9ef403719bfec098df3d4b0e8a2"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%",
    "summary": "AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.",
    "url": "https://finnhub.io/api/news?id=66af0f6dc5f1cb5421d4f7a57b4108420863bc56b14505318bcbbdd53f329b8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759859100,
      "headline": "Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%",
      "id": 137002788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.",
      "url": "https://finnhub.io/api/news?id=66af0f6dc5f1cb5421d4f7a57b4108420863bc56b14505318bcbbdd53f329b8a"
    }
  },
  {
    "ts": null,
    "headline": "Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care",
    "summary": "The Rare Disease Therapeutics Market is experiencing an unprecedented wave of innovation, driven by gene therapies, RNA-based treatments, enzyme replacement therapies (ERTs), and targeted biologics. According to DataM Intelligence, the Rare Disease Therapeutics Market Size reached US$ 135.88 billion in 2023, rose to US$ 154.64 billion in 2024, and is projected to reach US$ 495.27 billion by 2033, expanding at a CAGR of 13.8% during 2025–2033.",
    "url": "https://finnhub.io/api/news?id=ab39f8c16abd6bdfd8fb32b918f3a235397f60cf757e7ef69d08d758c0116eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759849200,
      "headline": "Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care",
      "id": 136999213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Rare Disease Therapeutics Market is experiencing an unprecedented wave of innovation, driven by gene therapies, RNA-based treatments, enzyme replacement therapies (ERTs), and targeted biologics. According to DataM Intelligence, the Rare Disease Therapeutics Market Size reached US$ 135.88 billion in 2023, rose to US$ 154.64 billion in 2024, and is projected to reach US$ 495.27 billion by 2033, expanding at a CAGR of 13.8% during 2025–2033.",
      "url": "https://finnhub.io/api/news?id=ab39f8c16abd6bdfd8fb32b918f3a235397f60cf757e7ef69d08d758c0116eeb"
    }
  },
  {
    "ts": null,
    "headline": "Melatonin Market to Reach USD 3.0 Billion by 2030 as Sleep Health, Supplements, and Clinical Applications Drive Global Demand",
    "summary": "The Melatonin Market is experiencing sustained growth as rising demand for sleep aids, dietary supplements, and medical applications accelerates adoption across healthcare and consumer sectors. According to DataM Intelligence, theMelatonin Market Size will reach USD 1.89 billion in 2025 and is projected to grow to USD 3.0 billion by 2030, recording a CAGR of 9.67% during 2025–2030.",
    "url": "https://finnhub.io/api/news?id=fedd2c569c6a9f7939c9af980a3946570c21c25d480634515a8d2de27e3b88af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759848000,
      "headline": "Melatonin Market to Reach USD 3.0 Billion by 2030 as Sleep Health, Supplements, and Clinical Applications Drive Global Demand",
      "id": 136999214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Melatonin Market is experiencing sustained growth as rising demand for sleep aids, dietary supplements, and medical applications accelerates adoption across healthcare and consumer sectors. According to DataM Intelligence, theMelatonin Market Size will reach USD 1.89 billion in 2025 and is projected to grow to USD 3.0 billion by 2030, recording a CAGR of 9.67% during 2025–2030.",
      "url": "https://finnhub.io/api/news?id=fedd2c569c6a9f7939c9af980a3946570c21c25d480634515a8d2de27e3b88af"
    }
  },
  {
    "ts": null,
    "headline": "Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?",
    "summary": "CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.",
    "url": "https://finnhub.io/api/news?id=53c7ced028caa008897d3d799fc2a989b0f1df85192061fb2770fc37a4eed18b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759847520,
      "headline": "Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?",
      "id": 136999215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.",
      "url": "https://finnhub.io/api/news?id=53c7ced028caa008897d3d799fc2a989b0f1df85192061fb2770fc37a4eed18b"
    }
  },
  {
    "ts": null,
    "headline": "Down 50%, Should You Buy the Dip on Pfizer?",
    "summary": "Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.",
    "url": "https://finnhub.io/api/news?id=0731b7f7486bfa13b42badc294a71eb7dbe426434935253cf7b2b56e0c5e5fca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759843800,
      "headline": "Down 50%, Should You Buy the Dip on Pfizer?",
      "id": 136999216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.",
      "url": "https://finnhub.io/api/news?id=0731b7f7486bfa13b42badc294a71eb7dbe426434935253cf7b2b56e0c5e5fca"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Delta Airlines, Levi Strauss, Pfizer, Zoom Communications , Fresnillo and Kyocera",
    "summary": "Zacks Analyst Blog features Delta Airlines, Levi Strauss, Pfizer, Zoom Communications, Fresnillo, and Kyocera as markets hit record highs despite a U.S. government shutdown.",
    "url": "https://finnhub.io/api/news?id=4a578b658148493a9cc5dced89e0b8a4e684101c93a7804c35a3e2af0429ead4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759843500,
      "headline": "The Zacks Analyst Blog Highlights Delta Airlines, Levi Strauss, Pfizer, Zoom Communications , Fresnillo and Kyocera",
      "id": 136999217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zacks Analyst Blog features Delta Airlines, Levi Strauss, Pfizer, Zoom Communications, Fresnillo, and Kyocera as markets hit record highs despite a U.S. government shutdown.",
      "url": "https://finnhub.io/api/news?id=4a578b658148493a9cc5dced89e0b8a4e684101c93a7804c35a3e2af0429ead4"
    }
  },
  {
    "ts": null,
    "headline": "AlphaSense Surpasses $500M in ARR as Adoption of Applied AI Workflows Surges",
    "summary": "AlphaSense, the AI platform redefining market intelligence for the business and financial world, today announced it has surpassed $500M in annual recurring revenue (ARR). This milestone reflects accelerating market adoption of AlphaSense's agentic workflows and AI capabilities, as well as growing demand for trusted, enterprise-wide AI insights that drive smarter decisions at scale. Today, over 6,500 customers trust AlphaSense to fuel their decision making, including Google, JP Morgan, Pfizer, Mi",
    "url": "https://finnhub.io/api/news?id=a64b2a021035497da0ac30ba7ea87ba1893a8a42131f7458a1ecb3c0f0222891",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759842900,
      "headline": "AlphaSense Surpasses $500M in ARR as Adoption of Applied AI Workflows Surges",
      "id": 136998664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AlphaSense, the AI platform redefining market intelligence for the business and financial world, today announced it has surpassed $500M in annual recurring revenue (ARR). This milestone reflects accelerating market adoption of AlphaSense's agentic workflows and AI capabilities, as well as growing demand for trusted, enterprise-wide AI insights that drive smarter decisions at scale. Today, over 6,500 customers trust AlphaSense to fuel their decision making, including Google, JP Morgan, Pfizer, Mi",
      "url": "https://finnhub.io/api/news?id=a64b2a021035497da0ac30ba7ea87ba1893a8a42131f7458a1ecb3c0f0222891"
    }
  },
  {
    "ts": null,
    "headline": "Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?",
    "summary": "MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.",
    "url": "https://finnhub.io/api/news?id=1abb297e6be03716f7053f6b96fee93e78e971ceb9e28854be00a15c20572caa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759840020,
      "headline": "Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?",
      "id": 136998886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.",
      "url": "https://finnhub.io/api/news?id=1abb297e6be03716f7053f6b96fee93e78e971ceb9e28854be00a15c20572caa"
    }
  },
  {
    "ts": null,
    "headline": "Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers",
    "summary": "The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact. Read more here.",
    "url": "https://finnhub.io/api/news?id=5caf82e2a0bfd6e3317ae238d44885b8bb9ee6ac3dbcf416cbdf46f73da88c86",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759838700,
      "headline": "Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers",
      "id": 137000589,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230554957/image_2230554957.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact. Read more here.",
      "url": "https://finnhub.io/api/news?id=5caf82e2a0bfd6e3317ae238d44885b8bb9ee6ac3dbcf416cbdf46f73da88c86"
    }
  },
  {
    "ts": null,
    "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? (Revised)",
    "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=4d2c7d54e41488c54dd6d9f80eff83910065229710e6b9a8882a8490f07381bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759835460,
      "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? (Revised)",
      "id": 136999220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=4d2c7d54e41488c54dd6d9f80eff83910065229710e6b9a8882a8490f07381bd"
    }
  },
  {
    "ts": null,
    "headline": "Venture financing for mRNA-based vaccines declines 82% in 2025 YTD",
    "summary": "Venture financing for companies developing innovator mRNA-based drugs more than halved from $1.1m in 2023 to $488m in 2024.",
    "url": "https://finnhub.io/api/news?id=aae9b6d6445a31bed6a4f562bd683198b440127972198066877d62432c14d0e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759832071,
      "headline": "Venture financing for mRNA-based vaccines declines 82% in 2025 YTD",
      "id": 136999221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Venture financing for companies developing innovator mRNA-based drugs more than halved from $1.1m in 2023 to $488m in 2024.",
      "url": "https://finnhub.io/api/news?id=aae9b6d6445a31bed6a4f562bd683198b440127972198066877d62432c14d0e5"
    }
  },
  {
    "ts": null,
    "headline": "Hiltzik: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer",
    "summary": "Trump and Pfizer said they reached a landmark deal to cut drug prices. Most Americans won't see a benefit, but Pfizer will.",
    "url": "https://finnhub.io/api/news?id=113c9d7b7c6d7d5f0dffdcebf18a23fdf8b2763619c818a2a17a708c1f2bcab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759831200,
      "headline": "Hiltzik: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer",
      "id": 136998824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Trump and Pfizer said they reached a landmark deal to cut drug prices. Most Americans won't see a benefit, but Pfizer will.",
      "url": "https://finnhub.io/api/news?id=113c9d7b7c6d7d5f0dffdcebf18a23fdf8b2763619c818a2a17a708c1f2bcab0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)",
    "summary": "Pfizer surged 15% last week on positive news, including a direct-to-consumer deal and a three-year tariff reprieve. Read why PFE stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=1d309a0268db5cbf2e579ffe87419161db685639920f774115d593d27aa74655",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759799800,
      "headline": "Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)",
      "id": 136994816,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer surged 15% last week on positive news, including a direct-to-consumer deal and a three-year tariff reprieve. Read why PFE stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=1d309a0268db5cbf2e579ffe87419161db685639920f774115d593d27aa74655"
    }
  }
]